Whiteside Theresa L
Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA.
Department of Immunology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA.
Cancer Microenviron. 2015 Dec;8(3):201-7. doi: 10.1007/s12307-014-0159-1. Epub 2014 Nov 12.
The role of regulatory T cells, (Treg) in human cancer and HIV-1 infections has been under intense scrutiny. While the lack of a marker specific for human Treg has made it challenging to phenotype these cells, combinations of several markers and functional attributes of Treg have made it possible to assess their contributions to immune homeostasis in health and disease. Treg diversity and their plasticity create a challenge in deciding whether they are beneficial to the host by down-regulating excessive immune activation or are responsible for adverse effects such as suppression of anti-tumor immune responses resulting in promotion of tumor growth. Treg are emerging as active participants in several biochemical pathways involved in immune regulation. This review attempts to integrate current information about human Treg in respect to their activities in cancer and HIV-1. The goal is to evaluate the potential of Treg as targets for future immune or pharmacologic therapies for cancer or HIV-1 infections.
调节性T细胞（Treg）在人类癌症和HIV-1感染中的作用一直受到密切关注。虽然缺乏人类Treg特异性标志物使得对这些细胞进行表型分析具有挑战性，但Treg的几种标志物和功能特性的组合使得评估它们在健康和疾病中对免疫稳态的贡献成为可能。Treg的多样性及其可塑性给判断它们通过下调过度免疫激活对宿主是否有益，还是对诸如抑制抗肿瘤免疫反应从而促进肿瘤生长等不良反应负责带来了挑战。Treg正成为参与免疫调节的几种生化途径的积极参与者。本综述试图整合关于人类Treg在癌症和HIV-1方面活动的当前信息。目的是评估Treg作为未来癌症或HIV-1感染免疫或药物治疗靶点的潜力。
